Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
28
investment:
Withheld
Endurance Sports TV (ESTV) is a portal that focuses on events like live racing, race reports, athlete biographies and documentaries. It aims to deliver engaging high-quality content via a Subscription-Video-On-Demand (SVOD) service available via web, mobile and TV mediums (Apple, Android, Firestick, Roku and Chromecast). ESTV has 81 million endurance sports fans and participants globally. The company’s app has seen more than 5000 downloads in over 100 countries. The platform also offers advertisement-free curated viewing to its viewers. ESTV has curated over 600 sports videos since 2019. The company will use the investment to focus on making video content broadcasting special features with global sports talent and covering top events. It will also use its PR & marketing teams to reach out to sports journalists and utilise social media channels to connect with fans and participants everywhere.
days to go:
Expired
investment:
£82,220
True Royalty Television is the first and only established TV channel serving the global millions of Royal super-fans, with 20,000 paying subscribers already on its platform. The British Royal Family is the 4th biggest brand in the world. With 350+ hours of top quality Royal content, refreshed monthly and with exclusive commissions, True Royalty curates relevant titles according to Royal news and the viewer's interest areas—British Royals, World Royals, and Royalty through history. There are 25 million people in the US alone who identify as both active Royal fans and who stream on-demand TV, up almost 300% from 8.6 million in 2018. The founders of the channel have assembled a diverse team of proven experts in TV production and distribution, digital marketing, PR, and brand partnerships from around the world. With the investment, the channel has identified partners for further growth opportunities including launching beyond the current US, Canada, Australia, NZ, UK & Ireland into India, Europe, the Middle East, and the Far East demographics.
days to go:
Expired
investment:
£2,148,699
paus is an on-demand streaming service. It offers specialist, hand-picked independent films to today's streamers who wish to avail a niche streaming service in 2020. The company aims to propel curated independent cinema into the $161 billion global streaming market by replacing conventional subscription and ad-based models with a peer-to-peer digital tipping model. paus is working with globally recognised film institutions to procure curated content. Over 1,900 people have signed up for early access to its iOS app. The company is currently rolling out a beta iOS version in the UK and US. It will use the investment to move into streaming theatre and web-series on its portal.
days to go:
Expired
investment:
£352,724
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
Jeeni is an online entertainment service that aims to harness the growing reach of streamed music. It has close to 350 million subscribers and a growth rate of 39% Year-on-Year (YoY) providing billion-dollar revenues for digital disruptors. The Jeeni prototype was launched in April 2019. The company asserts that it offers artists an ethical revenue share. Five revenue streams are operating in parallel on the Jeeeni platform, namely, subscription-based memberships, online masterclasses, bespoke hardware sales, pay-to-view streamed events, and branded merchandise sales. The company's long term goal is to surpass its target paid subscriber numbers, achieve high subscriber growth and exit by acquisition. The investment raised will be used to further scale the company's capacity globally and build its mass artist showcases.
days to go:
Expired
investment:
£118,854
